Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
The Bottom Line Forty million Americans taking GLP-1 drugs for weight loss, a meaningful decline in the national obesity rate, stabilizing diabetes diagnoses, and a new Medicare program offering $50 monthly access to Wegovy and Zepbound 2026 is shaping up as an inflection point for obesity treatment in the United States
This program is ideal for: Individuals whove plateaued with diet and exercise alone Those with PCOS, insulin resistance, or slow metabolism Postpartum women looking for safe weight loss options Clients seeking a non-surgical, expert-led solution Medications & Expectations Medications We Use: Semaglutide (Ozempic / Wegovy) Targets appetite and slows digestion for long-term weight control
The projected 18% reduction in cardiovascular events in persons who are overweight or are obese but without cardiovascular disease compares favorably to the recently announced top line results of the SELECT trial which studied Wegovy in persons with cardiovascular disease and showed an actual 20% reduction in future cardiovascular events
Some studies suggest it reduces liver fat, potentially benefiting liver health, while others indicate risks, especially for those with existing liver conditions
SARS-CoV-2 and ACE2 receptor interactions on endothelial cells lead to infection associated vascular injury, and the resultant activation of blood clotting machinery and immune responses
